A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)

NCT00427362 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
127
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Abbott